Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Urolithiasis
Erschienen in: Urolithiasis 5/2021

04.06.2021 | Original Paper

LITHOSCREEN: a comprehensive screening program and database for the assessment and treatment management of patients with kidney stones

verfasst von: William G. Robertson

Erschienen in: Urolithiasis | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

The aim of the LITHOSCREEN project was to construct a comprehensive screening program and database for recording and assessing the various risk factors for stone-formation in patients with urolithiasis. It is intended for use in Stone Clinics and is now being made available free of charge to researchers in the field who wish to maintain a comprehensive record of their patients’ medical histories, demographic backgrounds, lifestyle activities, metabolic abnormalities, biochemical risk of forming stones of various types, diet histories, stone analysis and long-term treatment records. From the recorded data for each patient, the program automatically calculates numerous functions important in the understanding of the clinical and chemical risk factors for stone-formation, including the renal handling of the ions involved, various metabolic functions, the biochemical risk of forming kidney stones (PSF), the Tiselius Indices of the supersaturation of urine with respect to calcium oxalate and calcium phosphate, the projected effects of changing the composition of each patient’s urinary composition on the risk of stone recurrence, and a program for analysing the diet of patients. It automatically produces one-page Summaries of each patient’s biochemical and dietary records with abnormal values highlighted according to a “traffic-light” colour-coding system and generates charts designed to improve patient compliance with treatment in the form of colour-coded “Target Diagrams” showing (a) the patient’s 24-h urine composition, (b) the patient's biochemical risk of forming stones of different types and (c) the composition of the patient’s diet. The Summary pages and “Target Diagrams” are suitable for inclusion in the patient’s Case Notes. LITHOSCREEN also produces charts projecting the effect of changing the composition of urine on the patient's biochemical risk of forming further stones. These graphs provide clues as to which urinary risk factors to target to reduce the patient’s risk of stone recurrence.
Literatur
1.
Robertson WG (1982) Urolithiasis: epidemiology and pathogenesis. In: Husain I (ed) Tropical urology and renal disease. Churchill Livingstone, Edinburgh, pp 143–164
2.
Smith LH (1989) The medical aspects of urolithiasis: an overview. J Urol 141(3 Pt 2):707–710CrossRef
3.
4.
Robertson WG, Peacock M, Nordin BEC (1968) Activity products in stone-forming and non-stone-forming urine. Clin Sci 34:579–594PubMed
5.
Tiselius H-G (1989) Standardized estimate of the ion activity product of calcium oxalate in urine from renal stone formers. Eur Urol 16:48–50CrossRef
6.
Kok DJ, Papapoulos SE (1993) Physicochemical considerations in the development and prevention of calcium. Bone Miner 20:1–15CrossRef
7.
Kavanagh JP (2006) Supersaturation and renal precipitation: the key to stone formation? Urol Res 34:81–85CrossRef
8.
Fleisch H, Bisaz S (1962) Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 203:671–675CrossRef
9.
Coe FL, Parks JH (1990) Defenses of an unstable compromise: crystallization inhibitors and the kidney’s role in mineral regulation. Kidney Int 38:625–631CrossRef
10.
Shiraga H, Min W, Van Dusen WJ, Clayman MD, Miner D, Terrell CH, Sherbotie JR, Foreman JW, Przysiecki C, Neilson EG (1992) Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 89:426–430CrossRef
11.
Ryall RL (1997) Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol 15:155–164CrossRef
12.
Cifuentes Delatte L, Minon-Cifuentes J, Medina JA (1985) Papillary stones: calcified renal tubules in Randall’s plaques. J Urol 133:490–494CrossRef
13.
Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M (2003) Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin Loops of Henle. J Clin Invest 111:607–616CrossRef
14.
Khan SR (2011) Crystal/cell interaction and nephrolithiasis. Arch Ital Urol Androl 83:1–5PubMed
15.
Robertson WG (2017) Do “inhibitors of crystallization” play any role in the prevention of kidney stones? A critique. Urolithiasis 45:43–56CrossRef
16.
Robertson WG (2004) The scientific basis of urinary stone-formation. In: Mundy AR, Fitzpatrick JM, Neal DE, George NJR (eds) Scientific basis of urology, 2nd edn. Taylor and Francis, London & New York, pp 205–227
17.
Robertson WG, Peacock M, Nordin BEC (1969) Calcium crystalluria in recurrent renal stone-formers. Lancet 2:21–24CrossRef
18.
Robertson WG, Peacock M, Marshall RW, Marshall DH, Nordin BEC (1976) Saturation-inhibitor index as a measure of the risk of calcium oxalate stone-formation in the urinary tract. N Engl J Med 294:249–252CrossRef
19.
Robertson WG (2015) Potential role of fluctuations in the composition of renal tubular fluid through the nephron in the initiation of Randall’s Plugs and calcium oxalate crystalluria in a computer model of renal function. Urolithiasis 43(Suppl 1):S93–S107CrossRef
20.
Robertson WG (1969) Measurement of ionized calcium in biological fluids. Clin Chim Acta 24:149–157CrossRef
21.
Werness PG, Brown CM, Smith LH, Finlayson B (1985) EQUIL2: a BASIC computer program for the calculation of urinary saturation. J Urol 134:1242–1244CrossRef
22.
Brown CM, Ackermann DK, Purich DL (1994) EQUIL93: a tool for experimental and clinical urolithiasis. Urol Res 22:119–126CrossRef
23.
Ashby RA, Byrne JP, Györy AZ (1999) Urine is a saturated equilibrium and not a metastable supersaturated solution: evidence from crystalluria and the general composition of calcium salt and uric acid calculi. Urol Res 27:297–305CrossRef
24.
May PM, Murray K (1991) JESS, a joint expert speciation system – 1. Raison d’être. Talanta 38:1409–1417PubMed
25.
Marangella M, Petrarulo M, Vitale C, Daniele P, Sammartano S (2021) LITHORISK.COM: the novel version of a software for calculating and visualizing the risk of renal stone. Urolithiasis 49:211–217
26.
Tiselius H-G, Larsson L (1981) Biochemical evaluation of patients with urolithiasis. Europ Urol 7:31–34CrossRef
27.
Tiselius H-G (1984) A simplified estimate of the ion-activity product of calcium phosphate in urine. Europ Urol 10:91–195CrossRef
28.
Robertson WG, Tiselius H-G, Rodgers AL Comparison of various indices of urinary supersaturation and biochemical risk of stone-formation (in preparation)
29.
Robertson WG, Peacock M, Heyburn PJ, Marshall DH, Clark PB (1978) Risk factors in calcium stone disease of the urinary tract. Br J Urol 50:449–454CrossRef
30.
Robertson WG (2003) A risk factor model of stone-formation. Frontiers Biosci 8:1330–1338CrossRef
31.
Dauw CA, Alruwaily AF, Bierlein MJ, Asplin JR, Ghani KR, Wolf JS Jr, Hollingsworth JM (2015) Provider variation in the quality of metabolic stone management. J Urol 193:885–890CrossRef
32.
Kok DJ (2012) Metaphylaxis, diet and lifestyle in stone disease. Arab J Urol 10:240–249CrossRef
33.
Pearle MS, Goldfarb DS, Assimos DG et al (2014) Medical management of kidney stones: AUA guideline. J Urol 192:316–324CrossRef
34.
Robertson WG (2012) General and specific dietary advice for the prevention of stone recurrence. In: Talati JJ, Tiselius H-G, Albala DM, Ye Z (eds) Urolithiasis–basic science and clinical practice. Springer, London, pp 709–720
35.
Robertson WG (2012) Methods for diagnosing the risk factors of stone-formation. Arab J Urol 10:250–257CrossRef
36.
Wu W, Yang B, Ou L, Liang Y, Wan S, Li S, Zeng G (2014) Urinary stone analysis on 12,846 patients: a report from a single center in China. Urolithiasis 42:39–43CrossRef
37.
Remer T, Manz F (1995) Potential renal acid load of foods and its influence on urine pH. J Am Diet Assoc 95:791–797CrossRef
38.
Robertson WG, Peacock M, Heyburn PJ, Hanes FA (1980) Epidemiological risk factors in calcium stone disease. Scand J Urol Nephrol 53(Suppl):15–28
39.
Ӧner M, Koutsoukos P, Robertson WG (2021) Kidney stones formation – thermodynamic, kinetic and clinical aspects, In: Amjad Z, Demadis K eds. Water-Formed Deposits: Fundamentals and Mitigation Strategies; chapter 25. Elsevier (in press)
40.
Hosking DH, Erickson SB, Van den Berg CJ, Wilson DM, Smith LH (1983) The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 130:1115–1118CrossRef
41.
Robertson WG, Peacock M (1985) The origin of metabolic abnormalities in primary calcium stone disease - natural or unnatural selection? In: Schwille PO, Smith LH, Robertson WG, Vahlensieck W (eds) Urolithiasis and related clinical research. Plenum Press, New York, pp 287–290CrossRef
Metadaten
Titel
LITHOSCREEN: a comprehensive screening program and database for the assessment and treatment management of patients with kidney stones
verfasst von
William G. Robertson
Publikationsdatum
04.06.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Urolithiasis / Ausgabe 5/2021
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-021-01276-0

Weitere Artikel der Ausgabe 5/2021

Urolithiasis 5/2021 Zur Ausgabe

Original Paper

Value of the color Doppler imaging mode in improving physicians’ diagnostic performance in patients with mid-ureteric stones larger than 5 mm: a retrospective study

Original Paper

Urine osmolality predicts calcium-oxalate crystallization risk in patients with recurrent urolithiasis

Original Paper

Does the duration between urine culture and percutaneous nephrolithotomy affect the rate of systemic inflammatory response syndrome postoperatively?

Original Paper

Emergency department and hospital revisits after ambulatory surgery for kidney stones: an analysis of the Healthcare Cost and Utilization Project

Original Paper

The characteristic and relationship of Escherichia coli isolated from urine and stones in patients with calcium oxalate stones

Original Paper

Urinary stone disease prevalence and associations in cystic fibrosis

Neu im Fachgebiet Urologie

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise